# Rejuvenate Biomed NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rejuvenate-biomed

- Industry: Pharmaceuticals
- Headquarters: Belgium
- Website: www.rejuvenatebiomed.com
- Total disclosed funding: $14M
- Latest round: Series B (Apr 15, 2022)
- Investors on record: 2

## About

Rejuvenate Biomed NV is dedicated to the development of AI-enabled combination drugs that focus on promoting healthy aging and improving muscle integrity in elderly patients suffering from age-related conditions.Founded in 2017 and headquartered in Belgium, Rejuvenate Biomed NV specializes in therapeutic solutions for age-related health issues. The company was founded by Ann Belien, who has a notable background in healthcare innovation. Their strategic focus has led to two funding deals, with the most recent being a Series B round in October 2021, raising EUR 15.7 million from investors including Rejuveron Life Sciences and Vesalius Biocapital. This funding round constitutes the entirety of their total amount raised.Rejuvenate Biomed is primarily focused on developing AI-enabled combination drugs aimed at promoting healthy aging. Their core product, RJx-01, is currently being evaluated in a Phase 2, double-blind, placebo-controlled clinical trial to determine its efficacy in maintaining muscle integrity in older patients experiencing muscle weakness and sarcopenia associated with chronic obstructive pulmonary disease (COPD). This clinical stage product addresses significant health concerns for elderly populations, specifically targeting age-related muscle degeneration and enhancing the quality of life for those affected. The company serves a diverse clientele, including healthcare providers and research institutions, with a focus on markets in Europe and North America, where there is a growing demand for solutions to age-related health issues.Rejuvenate Biomed's revenue structure is built around clinical partnerships and drug development collaborations. The company's offerings, including the flagship RJx-01, are positioned to engage in B2B transactions, where partnerships with research institutions and healthcare organizations facilitate the advancement of their clinical trials. Revenue generation stems from milestone payments associated with the development of their products, as well as potential licensing agreements once products reach market readiness. As the company progresses through various clinical stages, it is expected to establish commercial relationships that involve negotiated arrangements for the distribution and utilization of their therapeutics, reinforcing their position in the market for age-related healthcare solutions.In October 2021, Rejuvenate Biomed NV secured EUR 15.7 million in Series B funding to accelerate the clinical development of RJx-01 targeted at both acute and chronic sarcopenia. The company plans to utilize this funding to enhance its product pipeline and advance its clinical trials. Future initiatives include further development of RJx-01 and potential new products aimed at addressing additional age-related conditions. The company aims to expand its presence in North America and Europe, targeting specific markets with a growing need for innovative solutions in healthy aging. This strategy is aligned with their commitment to enhancing the quality of life for elderly populations.

## Funding rounds

- Series B, Apr 15, 2022, $14M — Vesalius Biocapital, Centenara Labs
- Series A, Mar 23, 2021, $0.5M — Vesalius Biocapital

## Investors

- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series A, Series B
- Centenara Labs (https://capitalatlas.ai/funds/centenara-labs) — Series B